<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lutz CS</submitter><funding>U.S. Department of Energy</funding><funding>Oak Ridge Institute for Science and Education</funding><funding>Centers for Disease Control and Prevention</funding><funding>Intramural CDC HHS</funding><pagination>4219-4230</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12288909</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(30)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>During the 2009 influenza A(H1N1)pdm09 pandemic, 77 countries received donated monovalent A(H1N1)pdm09 vaccine through the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative. However, 47% did not receive their first shipment until after the first wave of virus circulation, and 8% did not receive their first shipment until after the WHO declared the end of the pandemic. Arguably, these shipments were too late into the pandemic to have a substantial effect on virus transmission or disease burden during the first waves of the pandemic.&lt;h4>Objectives&lt;/h4>In order to evaluate the potential benefits of earlier vaccine availability, we estimated the number of illnesses and deaths that could be averted during a 2009-like influenza pandemic under five different vaccine-</pubmed_abstract><journal>Vaccine</journal><pubmed_title>Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.</pubmed_title><pmcid>PMC12288909</pmcid><funding_grant_id>CC999999</funding_grant_id><pubmed_authors>Bresee JS</pubmed_authors><pubmed_authors>Lafond KE</pubmed_authors><pubmed_authors>Azziz-Baumgartner E</pubmed_authors><pubmed_authors>Biggerstaff M</pubmed_authors><pubmed_authors>Reed C</pubmed_authors><pubmed_authors>Lutz CS</pubmed_authors><pubmed_authors>Porter RM</pubmed_authors><pubmed_authors>Rolfes MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.</name><description>&lt;h4>Background&lt;/h4>During the 2009 influenza A(H1N1)pdm09 pandemic, 77 countries received donated monovalent A(H1N1)pdm09 vaccine through the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative. However, 47% did not receive their first shipment until after the first wave of virus circulation, and 8% did not receive their first shipment until after the WHO declared the end of the pandemic. Arguably, these shipments were too late into the pandemic to have a substantial effect on virus transmission or disease burden during the first waves of the pandemic.&lt;h4>Objectives&lt;/h4>In order to evaluate the potential benefits of earlier vaccine availability, we estimated the number of illnesses and deaths that could be averted during a 2009-like influenza pandemic under five different vaccine-</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2026-03-31T10:48:30.431Z</modification><creation>2025-08-28T03:05:46.633Z</creation></dates><accession>S-EPMC12288909</accession><cross_references><pubmed>34119348</pubmed><doi>10.1016/j.vaccine.2021.05.006</doi></cross_references></HashMap>